B+
Bull case
22%
Probability
Target price
$270.00
+20.0% vs current
CAH
Cardinal HealthANYSE / Health Care Equipment & Services
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
53%
Probability
Target price
$250.00
+11.1% vs current
B-
Bear case
25%
Probability
Target price
$215.00
-4.4% vs current
AI sentiment snapshot
Latest data as of 2026-07-11
Recent news sentiment (30D)
+30.0
Positive
Company
-
Unavailable
Macro
+30.0
Positive
Pulse
-
Unavailable
Sentiment proxy
+53.3
Score
AI commentary
Available tone is mildly constructive because the latest primary evidence is an April 30, 2026 beat-and-raise and Barron's coverage framed the guidance increase positively. However, the packet does not include a fresh July company update, a usable social-context signal, or a dated company-confirmed event beyond follow-up monitoring of FY26 guidance delivery and segment execution, so sentiment should be treated as constructive but low-conviction.
RankAlpha Sentiment Codex - 2026-07-11
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-08-31catalystFY26 guidance delivery check after Q3 raiseMedium impact
Cardinal Health raised and narrowed FY26 non-GAAP EPS guidance to $10.70-$10.80 after Q3 FY26 revenue rose 11% to $60.9 billion and non-GAAP EPS rose 35% to $3.17; the next useful company-specific check is whether final FY26 results actually land within that raised range rather than merely extending the April beat-and-raise narrative [#SEC-8K-2026-04-30].
2026-12-31eventMedical distribution profit stabilization remains unresolvedMedium impact
Global Medical Products and Distribution revenue was roughly flat at $3.1 billion and segment profit fell 36% to $25 million as lower distribution volumes offset Cardinal Health brand growth; a turn in volumes or continued profit pressure is the clearest operating swing factor still visible in the primary evidence [#SEC-8K-2026-04-30].
2026-12-31eventNavista & ION remediation evidence after impairmentMedium impact
The Q3 filing disclosed a $184 million pre-tax goodwill impairment in Navista & ION tied to changes in the risk profile of business plans, business model updates, and base operational performance, making evidence of stabilization or further deterioration in that growth-business area a company-specific follow-up item [#SEC-8K-2026-04-30].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-11 • Updated nightlySource: Internal modelMethodology